Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report Journal Article


Authors: Barth, M. J.; Goldman, S.; Smith, L.; Perkins, S.; Shiramizu, B.; Gross, T. G.; Harrison, L.; Sanger, W.; Geyer, M. B.; Giulino-Roth, L.; Cairo, M. S.
Article Title: Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: A Children's Oncology Group report
Abstract: The ANHL01P1 trial was undertaken to determine pharmacokinetics and safety following the addition of rituximab to French-American-British/Lymphome Malins de Burkitt (FAB/LMB96) chemotherapy in 41 children and adolescents with Stage III/IV mature B-cell lymphoma/leukaemia. Patients received rituximab (375 mg/m2) days -2 and 0 of two induction cycles and day 0 of two consolidation cycles. Highest peak levels were achieved following the second dose of each induction cycle [299 ± 19 and 384 ± 25 μg/ml (Group-B); 245 ± 31 and 321 ± 32 μg/ml (Group-C)] with sustained troughs and t1/2 of 26-29 d. Rituximab can be safely added to FAB chemotherapy with high early rituximab peak/trough levels and a long t1/2. © 2013 John Wiley & Sons Ltd.
Keywords: adolescent; adult; child; clinical article; young adult; prednisone; doxorubicin; cancer combination chemotherapy; drug safety; antineoplastic agents; cytarabine; methotrexate; rituximab; cancer staging; drug megadose; neoplasm staging; multiple cycle treatment; etoposide; antineoplastic combined chemotherapy protocols; drug administration schedule; cyclophosphamide; vincristine; age factors; pediatric; b cell lymphoma; lymphoma, b-cell; cd20; pilot study; pilot projects; multicenter study; maximum plasma concentration; drug blood level; drug half life; l-lactate dehydrogenase; half-life; pharmacokinetics; non-hodgkin lymphoma; b cell leukemia; antibodies, monoclonal, murine-derived
Journal Title: British Journal of Haematology
Volume: 162
Issue: 5
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2013-09-01
Start Page: 678
End Page: 683
Language: English
DOI: 10.1111/bjh.12434
PROVIDER: scopus
PMCID: PMC3745786
PUBMED: 23802659
DOI/URL:
Notes: --- - "Export Date: 4 September 2013" - "CODEN: BJHEA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Lisa Giulino Roth
    16 Roth